Literature DB >> 464587

Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice.

H J Field, S E Bell, G B Elion, A A Nash, P Wildy.   

Abstract

Systemic treatment of mice with the nucleoside analog 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine [aciclovir]) was found to be highly effective against acute type 1 herpes simplex virus infection of the pinna. The drug ablated clinical signs and reduced virus replication both in tissue local to the inoculation site and within the nervous system. Provided that moderate-sized virus inocula were used, acycloguanosine treatment reduced or prevented the establishment of a latent infection in the dorsal root ganglia relating to the sensory nerve supply of the ear. However, although it aborted artificially produced infections in dorsal root ganglia, acycloguanosine was found not to be effective against the latent infection once established. This finding strongly indicated that latent herpes simplex virus in mice can exist in a nonreplicating form.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 464587      PMCID: PMC352710          DOI: 10.1128/AAC.15.4.554

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-04       Impact factor: 3.616

2.  Interaction of herpes virus and HeLa cells: comparison of cell killing and infective center formation.

Authors:  J T VANTSIS; P WILDY
Journal:  Virology       Date:  1962-06       Impact factor: 3.616

3.  The pathogenesis of pseudorabies in mice: virus replication at the inoculation site and axonal uptake.

Authors:  H J Field; T J Hill
Journal:  J Gen Virol       Date:  1975-01       Impact factor: 3.891

4.  A sensitive and precise plaque assay for herpes virus.

Authors:  W C RUSSELL
Journal:  Nature       Date:  1962-09-08       Impact factor: 49.962

5.  Biological activities of some purine arabinosides.

Authors:  G B Elion; J L Rideout; P de Miranda; P Collins; D J Bauer
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

6.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  Pathogenetic mechansims of recurrent herpes simplex virus infections.

Authors:  R J Klein
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

8.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

9.  The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice.

Authors:  H J Field; P Wildy
Journal:  J Hyg (Lond)       Date:  1978-10

10.  Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice.

Authors:  R J Klein; A E Friedman-Kien; A A Fondak; E Buimovici-Klein
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

View more
  50 in total

1.  Comprehensive quantification of herpes simplex virus latency at the single-cell level.

Authors:  N M Sawtell
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

2.  Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  L R Stanberry; S Kit; M G Myers
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

3.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease.

Authors:  A Simmons; A A Nash
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

5.  Tolerance and immunity in mice infected with herpes simplex virus: simultaneous induction of protective immunity and tolerance to delayed-type hypersensitivity.

Authors:  A A Nash; P G Gell; P Wildy
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

6.  A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections.

Authors:  A Wald; J Benedetti; G Davis; M Remington; C Winter; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

8.  Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model.

Authors:  A M Thackray; H J Field
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 9.  The role of oral acyclovir in the management of genital herpes simplex.

Authors:  S L Sacks
Journal:  CMAJ       Date:  1987-04-01       Impact factor: 8.262

10.  Acyclovir therapy of neonatal herpes simplex virus type 2 infections in rabbits.

Authors:  S E Sicher; J O Oh
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.